MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$33,464K
(51.94%↑ Y/Y)
Unrealized gain on
available-for-sale securities
$37K
(-87.06%↓ Y/Y)
Interest income
$4,068K
(-38.22%↓ Y/Y)
Gain on sale of
property and equipment
$674K
Foreign exchange gain /
(loss)
$14K
(128.57%↑ Y/Y)
Net loss
-$33,501K
(52.09%↑ Y/Y)
Total other income
$4,659K
(-27.19%↓ Y/Y)
Collaboration And Contracts
$12,601K
Non Cash Royalty
$1,482K
Interest expense
$97K
(-29.20%↓ Y/Y)
Loss from operations
-$38,160K
(50.00%↑ Y/Y)
Revenue
$14,083K
(128.21%↑ Y/Y)
Total operating
expenses
$52,243K
(-36.67%↓ Y/Y)
Change in fair value of
contingent consideration
-$1,830K
(-169.71%↓ Y/Y)
Research and development
$25,241K
(-53.29%↓ Y/Y)
General and
administrative
$15,893K
(-28.11%↓ Y/Y)
Restructuring costs
$12,939K
(247.82%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)